Prescription required. Can not be split. Product of India. Shipped from Mauritius. Farxiga is also marketed internationally under the name Forxiga.
Prescription required. Can not be split. Product of India. Shipped from Mauritius.
Prescription required. Can not be split. Product of India. Shipped from Mauritius. Farxiga is also marketed internationally under the name Forxiga.
Prescription required. May be split. Product of India. Shipped from Mauritius.
Farxiga (Dapagliflozin) and Forxiga are oral medications used to treat Type 2 diabetes in patients. Farxiga (Dapagliflozin) belongs to a class of drugs known as “sodium-glucose co-transporter 2 (SGLT2) inhibitors.” These work by helping the kidneys remove glucose from the bloodstream through the patient's rine. In addition to managing a patient’s blood sugar levels, Farxiga is also prescribed to reduce the risk of hospitalization for heart failure in adults with Type 2 diabetes and to treat chronic kidney disease.
This article will provide a comprehensive overview of Farxiga (dapagliflozin), a prescription medication approved for the treatment of type 2 diabetes mellitus, heart failure, and kidney disease. Dosing recommendations, indications, interactions and adverse effects of the drug will be explored, as will its role in improving glycemic control while reducing hospitalization for heart patients and type 2 diabetics. The information provided should assist both patients and healthcare providers to gain a better understanding of Farxiga, and the role it plays in improving treatment outcomes.
Farxiga is indicated for the treatment of type 2 diabetes mellitus to improve glycemic control.
The drug can also be used to reduce the risk of hospitalization for heart failure in patients with type 2 diabetes and cardiovascular disease.
Study data suggests Farxiga reduces the risk of hospitalization and fatality for diabetic and non-diabetic patients.
Farxiga can also reduce the risk of kidney disease progression, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease who are at risk of progression.
To comply with Canadian International Pharmacy Association regulations you are permitted to order a 3-month supply or the closest package size available based on your personal prescription. read more
Here are general precautions when taking Farxiga (dapagliflozin):
Type | Precaution |
Dehydration | May cause dehydration; ensure adequate fluid intake, especially in hot weather or when exercising. |
Kidney Function | Regular monitoring of kidney function is necessary; not recommended for patients with severe renal impairment. |
Hypoglycemia | When used with insulin or insulin secretagogues, there is an increased risk of low blood sugar. |
Genital Infections | Can increase the risk of genital mycotic infections; maintain good hygiene and monitor for symptoms. |
Urinary Tract Infections | May increase the risk of urinary tract infections; report symptoms to a healthcare provider. |
Ketoacidosis | Rare cases of diabetic ketoacidosis reported; watch for symptoms like nausea, vomiting, and abdominal pain. |
Bladder Cancer | Not recommended for patients with active bladder cancer; discuss risks with your doctor. |
Hypotension | May cause a drop in blood pressure, especially in patients on diuretics or with low blood pressure. |
Fractures | Possible increased risk of bone fractures; consider the risk-benefit ratio in patients at risk. |
Pregnancy and Breastfeeding | Not recommended during pregnancy or breastfeeding; discuss with your healthcare provider. |
Here are other risk factors associated with taking Farxiga (dapagliflozin):
Warning/Precaution | Additional Risk Information |
Ketoacidosis Risk | There are some reports of ketoacidosis in patients using SGLT2 inhibitors, including Farxiga, even if blood glucose levels are <250 mg/dL. Symptoms include excessive thirst, frequent urination, nausea, and abdominal pain. |
Volume Depletion Risk | Farxiga has been known to cause intravascular volume depletion, leading to symptomatic hypotension or changes in creatinine. Patients with impaired renal function, elderly patients, or those on loop diuretics are at increased risk. |
Urinary Tract Infections Risk | Increased risk of serious urinary tract infections may occur, including urosepsis and pyelonephritis. Patients should be evaluated and monitored for signs and symptoms of urinary tract infections. |
Hypoglycemia Risk with Insulin/Secretagogues | Increased risk of hypoglycemia when combined with insulin or insulin secretagogues. It may be necessary to lower the dose of insulin or secretagogue. Symptoms of hypoglycemia include dizziness, confusion, and sweating. |
Necrotizing Fasciitis Risk | Rare cases of necrotizing fasciitis (Fournier's gangrene) have been reported. Symptoms include pain or tenderness, erythema, and swelling in the genital or perianal area, fever, and malaise. |
Here are general dosage requirements for Farxiga (dapagliflozin):
Treatment of Condition | Initial Dose | Maintenance Dose | Maximum Dose |
Type 2 Diabetes | 5 mg once daily | May increase to 10 mg once daily | 10 mg once daily |
Chronic Kidney Disease | 10 mg once daily | Not applicable | 10 mg once daily |
Heart Failure | 10 mg once daily | Not applicable | 10 mg once daily |
Renal Impairment (eGFR <45 mL/min/1.73 m²) | Not recommended | Not recommended | Not recommended |
Common side effects include the following:
anxiety
bladder pain
bloody or cloudy urine
blurred vision
chills
cold sweats
confusion
cool, pale skin
decreased frequency or amount of urine
depression
difficult, burning, or painful urination
dizziness
fast heartbeat
frequent urge to urinate
headache
increased hunger
increased thirst
itching of the vagina or genitals
loss of appetite
loss of consciousness
lower back or side pain
nausea
nightmares
seizures
shakiness
slurred speech
swelling of the face, fingers, or lower legs
thick, white vaginal discharge with mild or no odor
trouble breathing
unusual tiredness or weakness
vomiting
weight gain
If you experience any of these side effects, discontinue use right away and contact your primary care physician to learn about alternatives.
Dapagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. These class of medications help to manage blood sugar levels by causing the kidneys to get rid of more glucose in the urine.
Please make sure to consult with your physician to get personalized directions.
Usually, the recommended starting dose for Farxiga for glycemic control is 5 mg orally once daily, which can be increased to 10 mg orally once daily. It is important to assess volume status and correct volume depletion before initiating treatment.
More information may be found in the product monograph (page 26) - here.
Contraindications include a history of serious hypersensitivity reaction to the medication and patients on dialysis or with moderate to severe renal impairment. These individuals should not take Farxiga due to potential risks and serious adverse reactions associated with its use.
Please refer to the drug's monograph (page 4) - here.
Cases of diabetic ketoacidosis have been reported in patients with type 2 diabetes mellitus who are on a regimen of Farxiga.
Ketoacidosis may occur even with blood glucose values below 13.9 mmol/L (250 mg/dL).Patients should be assessed immediately if any of the following symptoms occur: nausea, vomiting, difficulty breathing, confusion, excessive thirst, anorexia, abdominal pain, and unusual fatigue or sleepiness, regardless of blood glucose level.
For more details, please refer to the drug monograph (page 4) - here.
Farxiga sometimes can cause volume depletion. It can lead to symptomatic hypotension or acute transient changes in creatinine.
More information regarding this phenomenon may be found in this FDA Document (page 5.2) - here.
There is an increased risk of urinary tract infections in patients treated with Farxiga. Post-marketing reports show some cases of serious urinary tract infections, including urosepsis and pyelonephritis, with following hospitalization.
The content on this page is for informational and educational purposes only and does not constitute professional medical advice. Patients should not use the information presented on this page for diagnosing a health-related issue or disease. Before taking any medication or supplements, patients should always consult a physician or qualified healthcare professional for medical advice or information about whether a drug is safe, appropriate or effective.